Topics

Arecor and JDRF sign a joint research, development and commercialisation agreement to develop a co-formulation insulin for the treatment of diabetes

08:08 EDT 25 Oct 2019 | OBN

Arecor Ltd, the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has signed a Research, Development and Commercialisation agreement with JDRF, the leading global organization funding type 1 diabetes (T1D) research.

Original Article: Arecor and JDRF sign a joint research, development and commercialisation agreement to develop a co-formulation insulin for the treatment of diabetes

NEXT ARTICLE

More From BioPortfolio on "Arecor and JDRF sign a joint research, development and commercialisation agreement to develop a co-formulation insulin for the treatment of diabetes"

Quick Search

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Nephrology - kidney function
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...